Evidence map›Paper›PMID 34826223›Full record

ReviewThe British journal of radiology2022

Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer.

Alexander P Cole, Bjoern J Langbein, Francesco Giganti, Fiona M Fennessy, Clare M Tempany, Mark Emberton

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The British journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Innovations in prostate cancer: introductory editorial.The British journal of radiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexander P ColeDivision of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-0049-8529
Bjoern J LangbeinDivision of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Francesco GigantiDepartment of Radiology, University College London Hospital NHS Foundation Trust, London, UK.
Fiona M FennessyDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Clare M TempanyDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mark EmbertonDepartment of Urology, University College London Hospitals NHS Foundation Trust, London, UK.

Funding

Image Guided Therapy Center - Ultrasound-based sensor system for the monitoring of COVID-19 patientsP41EB015898 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI TEMPANY, CLARE M · 2012 to 2021
$18.9M
TRD 3 - Enabling Technologies for Intraprocedural GuidanceP41EB028741 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI Carl-Fredrik Westin · 2021 to 2026
$10.7M
NIBIB NIH HHS P41 EB015898NIBIB NIH HHS P41 EB028741
6 · The paper itself

Abstract

The role of multiparametric MRI in diagnosis, staging and treatment planning for prostate cancer is well established. However, there remain several challenges to widespread adoption. One such challenge is the duration and cost of the examination. Abbreviated exams omitting contrast-enhanced sequences may help address this challenge. In this review, we will discuss the rationale for biparametric MRI for detection and characterization of clinically significant prostate cancer prior to biopsy and synthesize the published literature. We will weigh up the advantages and disadvantages to this approach and lay out a conceptual cost/benefit analysis regarding adoption of biparametric MRI.

Indexed as

BiopsyContrast MediaCost-Benefit AnalysisHumansMaleMultiparametric Magnetic Resonance ImagingNeoplasm GradingNeoplasm StagingProstatic NeoplasmsContrast Media

Identifiers

PMID34826223
PMCPMC8978228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.